FTRE

Fortrea Holdings Inc.

$21.39

-3.82%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M+6.7%
3M+11.6%
YTD+26.7%
1Y+112.3%
52-week range—
Beta1.81
Full chart and returns against a benchmark

Q-Score

53/ 100

Quality against peers; 50 is the peer median.

Growth50
Risk51
Performance47
Valuation66
Profitability62
Leverage26
Sentiment58
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$2.7B+1.0%
Net income-$986.2M
Net margin-36.2%-24.0 pts
Historical fundamentals

Revenue exposure

North America47%
Europe31%
Other Geographical Areas21%
Largest customer18%
Regions, segments, customers and suppliers

Valuation

FTREIndustryP/E—89.69P/S0.7711.88EV/EBITDA31.6867.10P/B3.886.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Oct 29next report, before the open
EPS estimate$0.22
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate